Aytu Biopharma (AYTU) Corporate presentation summary

Mission and therapeutic focus

• Focuses on improving patient lives, especially those with complex CNS conditions like MDD and ADHD.

• Portfolio includes novel therapeutics for major depressive disorder and attention deficit hyperactivity disorder.

Product portfolio and innovation

• Features differentiated, patent-protected prescription brands primarily for CNS, ADHD, and pediatric conditions.

• EXXUA, a first-in-class 5HT1A agonist for MDD, offers efficacy without common antidepressant side effects.

• ADHD brands include Adzenys XR-ODT and Cotempla XR-ODT, both extended-release orally disintegrating tablets.

• Pediatric brands include Karbinal ER and unique multivitamin supplements.

Commercial infrastructure and patient access

• Proprietary Aytu RxConnect program ensures broad, affordable access and high patient adherence.

• Lean, scalable commercial infrastructure with direct sales force and analytics platform supports rapid expansion.